Market research
VX1.F Vertex Pharmaceuticals Incorporated
F EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 115B
- P/E ratio
- 30.89
- Analyst target
- 258.59
- Dividend yield
- Not available
- Beta
- 0.28
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 115B
- P/E ratio
- 30.89
- Analyst target
- 258.59
- Dividend yield
- Not available
- Beta
- 0.28
About
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Research context
Vertex Pharmaceuticals Incorporated appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VX1.F discussion.
5 years, 6 months ago
Vertex Pharmaceuticals Incorporated is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.1.
Vertex Pharmaceuticals Incorporated's total revenue rose by 15.2% to $2B since the same quarter in the previous year.
Its net income has increased by 3.6% to $604M since the same quarter in the previous year.
Finally, its free cash flow grew by 3.4% to $444M since the same quarter in the previous year.
Based on the above factors, Vertex Pharmaceuticals Incorporated gets an overall score of 4/5.